Table 2.

Important clinical events (number of episodes in patients) in the study cohort.

	Alemtuzumab Group N=35	Non-Alemtuzumab Group N=50	P value
Infectious syndromes % (n/N)
Probable invasive aspergillosis	3% (1/35)	4% (2/50)	1.0
CMV Infection/Disease	9% (3/35)	28% (14/50)	0.07
Gram negative Pneumonia	14% (5/35)	2% (1/50)	0.07
Gram positive Pneumonia	11% (4/35)	2% (1/50)	0.15
Culture negative Tracheobronchitis	11% (4/35)	0% (0/50)	-
Culture negative Pneumonia	2% (1/50)	10% (5/50)	0.3
Histologically proven (ACR)
Minimal	48% (18/35)	24% (12/50)	0.012
Mild	31% (11/35)	6% (3/50)	0.03
Moderate	22% (8/35)	0% (0/50)	-
Severe	6% (2/35)	0% (0/50)	-